Metabolic alterations present in obesity and correlation with Non-Alcoholic Fatty Liver Disease (NAFLD)
Abstract
Currently in the world, thousands of people are somewhat overweight. Obesity, mainly characterized by the accumulation of fat in adipose tissue can cause various damages in the body, incluind Metabolic Syndrome. There is a high correlation between patients with this syndrome and those with Non-Alcoholic Fatty Liver Disease (NAFLD), being defined as the increase of the deposition of lipids in the liver in the absence of excessive consumption of alcohol. Excess intake of saturated fatty acids, increased free fatty acids derived from white adipose tissue lipolysis, reduced β-oxidation along with an increase in de novo lipogenesis and decreased synthesis or secretion of VLDL in hepatocytes contribute to the Hepatic steatosis. The treatment for these pathologies is initially based on diet changes and physical activity practice. In addition, there are still some classes of medicines available to treat the accumulation of fat in the liver as well as decrease insulin resistance. Studies still seek to find specific medicines for the treatment of NAFLD, therefore, the most effective method continues to be prevention, through an improvement in the quality of life, related to a balanced diet and the practice of regular physical activity.
Keywords
References
Turi BC, Codogno JS, Fernandes RA, Monteiro HL. Low levels of physical activity and metabolic syndrome: cross-sectional study in the brazilian public health system. Ciência & saúde coletiva 2016; 21: 1043-1050. http://dx.doi.org/10.1590/1413-81232015214.23042015
Leung L, Birtwhistle R, Hannah S. Anti-diabetic and hypoglycaemic effects of momordica charantia (bitter melon): a mini review. Br J nutr. 2009; 102: 1703-1708. https://doi.org/10.1017/S0007114509992054
Ezzati M. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. The Lancet. 2016; 397: 1377-1396. https://doi.org/10.1016/S0140-6736(16)30054-X
Reiff and Vieira AC, Sichieri R. Association of Socioeconomic Status with Obesity. Revista de Saúde Coletiva 2008; 18: 415-426. http://dx.doi.org/10.1590/S0103-73312008000300003
Dias PC, Henriques P, Anjos LA, Burlandy L. Obesity and public policies: the Brazilian government’s definitions and strategies. Cad. Saúde Pública 2017; 33:1-12. http://dx.doi.org/10.1590/0102-311x00006016
Hoo RLC, Yeung DCY, Lam KSL, Xu A. Inflammatory biomarkes associated with obesity and insulin resistance: a focus on lipocalin-2 and adipocyte fatty acid-binding protein. Expert. Rev. Endocrinol. Metab. 2008; 3: 29-41. https://doi.org/10.1586/17446651.3.1.29
Rose AJ; Richter, EA. Skeletal muscle glucose uptake during exercise: how is it regulated. Physiology 2005; 20: 260-270. https://doi.org/10.1152/physiol.00012.2005
Silva CA, Lopes FS, Serafim M, Botura E, Rocha e Silva RC, Marques FAO, Melo SI. Effect of high-intensity exercise on endothelial function in patients with t2dm. Rev bras med esporte 2016; 22: 126 – 130. http://dx.doi.org/10.1590/1517-869220162202151254
Postic C, Dentin R; Girald J. Role of the liver in the control of carbohydrate and lipid homeostasis. Diabetes metabol. 2004; 398-408. https://doi.org/10.1016/S1262-3636(07)70133-7
Birnbaum MJ. Diabetes: dialogue between muscle and fat. Nature 2001; 409: 672-673. http://dx.doi.org/10.1038/35055643
Stout DL, Fugate SE. Thiazolidinediones for treatment of polycystic ovary syndrome. Pharmacotherapy 2005; 244-252. https://doi.org/10.1592/phco.25.2.244.56943
Borges MC, Terra GA, Takeuti TD, Ribeiro BM, Silva AA, Terra-Junior JA, Rodrigues-Junior V, Crema E. Immunological evaluation of patients with type 2 diabetes mellitus submitted to metabolic surgery. Abcd arq bras cir dig. 2015; 28: 266-269. https://dx.doi.org/10.1590%2FS0102-6720201500040012
Yang G, Li Y, Cui L, Jiang H, Li X et al. Increased plasma dipeptidyl peptidase-4 activities in patients with coronary artery disease. Plos one 2016; 11: 1-14. https://doi.org/10.1371/journal.pone.0163027
Onge EL, Miller S, Clements E. Sitagliptin/Metformin (Janumet) as Combination Therapy In the Treatment of Type-2 Diabetes Mellitus. Pharmacy and Therapeutics 2012; 37: 699-708.
Pecoits-Filho R, Abensur H, Betonico CCR, Machado AD, Parente EB et al. Interactions between kidney disease and diabetes: dangerous liaisons. Diabetol Metab Syndr. 2016; 8: 1-21. https://dx.doi.org/10.1186%2Fs13098-016-0159-z
Hassan K, Bhalla V, Regal ME, A-Kader H. Decrease of liver fat content by aerobic exercise or metformin therapy in overweight or obese women. Rev invest clin. 2014; 65: 307-317. https://dx.doi.org/10.3748%2Fwjg.v20.i34.12082
Paglialunga S, Dehn CA. Clinical assessment of hepatic de novo lipogenesis in non-alcoholic fatty liver disease. Lipids in health and disease 2016; 15: 1-10. https://dx.doi.org/10.1186%2Fs12944-016-0321-5
Ahmed M. Non-alcoholic fatty liver disease in 2015. World J Hepatol. 2015; 7: 1450-1459. https://doi.org/10.1093/bmb/ldw031
Nagle CA, Klett EL, Coleman RA. Hepatic triacylglycerol accumulation and insulin resistance. J lipid res. 2009; 50: 74-79. https://doi.org/10.1194/jlr.R800053-JLR200
Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. J hepatol. 2013; 58: 1007-1019. https://doi.org/10.1016/j.jhep.2012.11.021
Monjardim RF, Costa DMC, Romano RFT, Salvadori PS, Santos JVC et al. Diagnosis of hepatic steatosis by contrast-enhanced abdominal computed tomography. Radiol Bras. 2013; 46: 134-138. http://dx.doi.org/10.1590/S0100-39842013000300005
Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48: 792-798. https://doi.org/10.1002/hep.22429
Hassan K, Bhalla V, El Regal ME, A-Kader H. Decrease of liver fat content by aerobic exercise or metformin therapy in overweight or obese women. Rev invest clin. 2013; 65: 307-317. https://dx.doi.org/10.3748%2Fwjg.v20.i34.12082
Cussons AJ, Watts GF, Mori TA, Stuckey BG. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J clin endocrinol metab. 2009; 94: 3842-3848. https://doi.org/10.1210/jc.2009-0870
Ratziu V, Giral P, Jacqueminet S. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (flirt) trial. Gastroenterology 2008; 135: 100-110. https://doi.org/10.1053/j.gastro.2008.03.078
Mathurin P, Hollebecque A, Arnalsteen L. Prospective study of the longterm effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009; 137: 532-540. https://doi.org/10.1053/j.gastro.2009.04.052
Marin-Penalver JJ, Martin-Timon I, Sevillano-Collantes C, Del Canizo-Gomez FJ. Update on the treatment of type 2 diabetes mellitus. World journal of diabetes 2016; 7: 354-395. https://doi.org/10.4239/wjd.v7.i17.354
Mcardle WD, Katch FI, Fatch VL. Fisiologia do exercício – Nutrição, energia e desempenho humano. 7ª ed. Rio de Janeiro: Guanabara Koogan, 2011: 1132p.
Takahashi H, Alves CRR, Stanford KI, Middelbeek RJW, Nigro P et al. TGF-β2 is an exercise-induced adipokine that regulates glucose and fatty acid metabolismo. Nature Metabolism 2019; 1: 291-303. http://doi.org/10.1038/s42255-018-0030-7
Sousa AV, Guedes JC, Filho MLM, Condessa VA, Condessa LA et al. Nonalcoholic fatty liver disease: literature review. Revista Ciências em Saúde 2014; 4: 1-10. http://dx.doi.org/10.21876/rcsfmit.v4i1.167
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 3.0 License.